IMVT Latest Headlines

Stifel Nicolaus Keeps Their Buy Rating on Immunovant (IMVT)

at www.tipranks.com (Tue, 10-Feb 9:05 PM)

Immunovant (IMVT) Gets a Buy from Oppenheimer

at www.tipranks.com (Tue, 10-Feb 12:35 PM)

Undervalued Potential in Difficult-to-Treat RA: Buy Rating on Immunovant Driven by IMVT-1402’s Differentiated Profile and Underappreciated Market Opportunity

at www.tipranks.com (Tue, 10-Feb 6:36 AM)

Immunovant Rides Brepocitinib Momentum Into 2026

at www.tipranks.com (Mon, 9-Feb 7:20 PM)

Immunovant (IMVT) Receives a Buy from J.P. Morgan

at www.tipranks.com (Mon, 9-Feb 7:17 AM)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunovant (IMVT) and Roivant Sciences (ROIV)

at www.tipranks.com (Sun, 8-Feb 12:20 PM)

Immunovant’s $550 Million Stock Offering Extends Cash Runway Toward Graves’ Disease Launch

Market Chameleon (Thu, 11-Dec 11:12 AM)

Immunovant’s $550 Million Financing Targets Graves' Disease Launch: Capital Injection Aims to Extend Cash Runway and Advance IMVT-1402

Market Chameleon (Thu, 11-Dec 8:38 AM)